<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemoprevention of urothelial carcinoma of the bladder</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemoprevention of urothelial carcinoma of the bladder</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chemoprevention of urothelial carcinoma of the bladder</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven C Campbell, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Seth P Lerner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Urothelial carcinoma of the bladder is a common malignancy of the urinary tract. Most cases of urothelial carcinoma of the bladder can be attributed to smoking and occupational and environmental carcinogen exposures, which cause diffuse changes in the urothelium and eventually result in bladder cancer. The identification of these risk factors provides an opportunity to minimize the incidence of bladder cancer through smoking cessation programs and decreasing exposure to workplace carcinogens [<a href="#rid1">1-3</a>]. (See  <a class="medical medical_review" href="/d/html/2957.html" rel="external">"Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder", section on 'Risk factors'</a>.)</p><p>Other potentially useful approaches include increasing cruciferous vegetable [<a href="#rid4">4-7</a>] and fluid intake [<a href="#rid8">8</a>], decreasing dietary fat [<a href="#rid9">9</a>], and losing weight [<a href="#rid10">10</a>]. Epidemiologic data suggesting that an increased intake of cruciferous vegetables (eg, cabbage, broccoli, and mustard) is associated with a reduced incidence of bladder cancer appear promising, and this is an active area of research [<a href="#rid5">5,6</a>]. However, all of these lifestyle-related factors must be placed in the context of possible predisposing genetic factors, which are poorly understood [<a href="#rid11">11</a>].</p><p>Chemoprevention is the use of systemic agents to prevent or reverse these changes. Primary chemoprevention seeks to block the formation of de novo bladder cancers in healthy individuals, while secondary chemoprevention focuses on avoiding the formation of additional tumors in patients who have already been treated for bladder cancer. Although chemoprevention is not routinely recommended in either primary or secondary settings, it is an area of active clinical investigation.</p><p>The chemoprevention of bladder cancer with systemic agents is reviewed here, with the focus primarily on agents for which epidemiologic or clinical trial data are available. The use of intravesical agents to prevent the recurrence of non-muscle invasive bladder cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/2996.html" rel="external">"Treatment of primary non-muscle invasive urothelial bladder cancer"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>Premalignant and malignant changes occur in the urothelium of the urinary tract that are chronically exposed to environmental carcinogens in a process referred to as field cancerization. Within this exposed field, chemical carcinogens damage DNA in the urothelial cell epithelium, allowing cancer to develop from multiple clones. These carcinogens are excreted in the urine and stored temporarily in the bladder, where they have an extended opportunity to interact with the urothelium. The gradual accumulation of chromosomal damage in the urothelial cells eventually results in phenotypic expression and transformation into overt neoplasm.</p><p>These carcinogens form highly reactive electrophilic species that bind nucleic acid and induce structural mutations within bladder epithelial cells. The observed changes (which may vary in different cells) include allelic deletions, loss of heterozygosity, inactivation of tumor suppressor genes, or activation of proto-oncogenes. The molecular mechanisms and pathways associated with the development of bladder cancer are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2957.html" rel="external">"Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder"</a>.)</p><p>Effective chemopreventive agents may act by preventing initial damage, enhancing repair, or blocking specific neoplastic processes (such as angiogenesis and invasion) that are involved in the transformation into invasive bladder cancer. In addition, increased urine output (attained by increased fluid intake) works to flush carcinogens out of the bladder, thereby minimizing exposure time.</p><p class="headingAnchor" id="H5"><span class="h1">TARGET POPULATION</span><span class="headingEndMark"> — </span>Effective bladder cancer chemoprevention is facilitated by the elucidation of appropriate target populations.</p><p>The identification of risk factors for bladder cancer identifies populations for whom primary chemoprevention could be of potential utility [<a href="#rid12">12-14</a>]. These risk factors include (see  <a class="medical medical_review" href="/d/html/2957.html" rel="external">"Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder", section on 'Environmental factors'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Tobacco use or heavy second-hand smoke exposure</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to aniline dyes</p><p class="bulletIndent1"><span class="glyph">●</span>Long-term use of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a></p><p class="bulletIndent1"><span class="glyph">●</span>History of pelvic radiation</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to chemical carcinogens associated with certain industries (eg, rubber or leather production, aluminum smelting, and exposure to diesel exhaust)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic factors</p><p></p><p>The known high rate of relapse after the diagnosis and treatment of early-stage bladder cancer allows the identification of a separate population for whom secondary chemoprevention may be valuable.</p><p class="headingAnchor" id="H6"><span class="h1">CHEMOPREVENTIVE AGENTS</span><span class="headingEndMark"> — </span>No agent has an established role in either primary or secondary chemoprevention of bladder cancer.</p><p>The agents that have been most widely evaluated include vitamins, micronutrients, and various synthetic compounds [<a href="#rid15">15</a>]. The rationale and available data for the most widely clinically or epidemiologically evaluated agents will be reviewed here.</p><p class="headingAnchor" id="H7"><span class="h2">Retinoids</span><span class="headingEndMark"> — </span>Retinoids (<a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> analogues) are modulators of differentiation and proliferation in epithelial cells and can serve as potent inhibitors of neoplastic transformation [<a href="#rid16">16</a>]. Laboratory studies demonstrated that rats deficient in vitamin A are more susceptible to environmentally induced bladder carcinogenesis [<a href="#rid17">17</a>] and that retinoid supplements could prevent carcinogen-induced bladder cancer [<a href="#rid18">18-20</a>].</p><p>However, clinical data do not support the use of retinoids for primary chemoprevention:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis published in 2000 that included six case-control studies reported no association between the risk of bladder cancer and low dietary intake of either retinol or <a class="drug drug_general" data-topicid="9127" href="/d/drug information/9127.html" rel="external">beta-carotene</a> [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No benefit was observed using retinoids for primary chemoprevention in the Alpha-Tocopherol, <a class="drug drug_general" data-topicid="9127" href="/d/drug information/9127.html" rel="external">Beta-Carotene</a> (ATBC) Study. The ATBC Study included more than 29,000 male smokers who were randomly assigned to primary prevention using beta-carotene, alpha-tocopherol (a <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> precursor), both, or placebo [<a href="#rid21">21,22</a>]. At a median follow-up of 6.1 years, there was no difference in the incidence of bladder cancer regardless of whether patients were or were not taking alpha-tocopherol (81 versus 74 cases) or retinoids (79 versus 76 cases); however, the power of the study to detect a benefit was limited by the low incidence of bladder cancer in both groups.</p><p></p><p>The use of retinoids for secondary chemoprevention has been assessed in several clinical trials, with conflicting results. Thus, the administration of retinoids should be done only in the context of a well-designed clinical trial.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etretinate</strong> – Two randomized trials were conducted to evaluate the role of etretinate, a synthetic retinoid, for secondary prevention among patients who had been treated for non-muscle invasive bladder cancer [<a href="#rid23">23,24</a>]. While both trials showed a significant reduction in the rate of recurrence, predominantly in patients with grade 1 or 2 tumors [<a href="#rid23">23</a>] or Ta to T1 tumors [<a href="#rid24">24</a>], the toxicities were significant and included deaths from myocardial infarction in both studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fenretinide</strong> – Two studies evaluated the efficacy of fenretinide for the prevention of a recurrence of non-muscle invasive bladder cancer following transurethral resection of bladder tumors [<a href="#rid25">25,26</a>]. Fenretinide was well tolerated, without serious adverse effects; however, neither study observed a positive impact on the recurrence risk for these patients. In the larger trial, 137 patients with resected non-muscle invasive bladder cancer were randomly assigned to fenretinide or placebo. The risk of recurrence at one year did not differ significantly between both arms (32 percent), and the trial was closed early, before meeting its accrual goal [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Side effects have been a concern with chronic prophylactic administration of retinoids. Synthetic retinoids with reduced side effects or retinoids encapsulated into novel delivery systems may improve tolerability and outcomes with these agents [<a href="#rid27">27</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Pyridoxine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9839" href="/d/drug information/9839.html" rel="external">Pyridoxine</a> (vitamin B6) has been studied as a means to counteract the abnormalities in tryptophan metabolism that result in the high levels of tryptophan metabolites observed in patients with bladder cancer [<a href="#rid28">28</a>].</p><p>Two randomized clinical trials investigating the use of <a class="drug drug_general" data-topicid="9839" href="/d/drug information/9839.html" rel="external">pyridoxine</a> for secondary chemoprevention of bladder cancer have not demonstrated a positive effect:</p><p class="bulletIndent1"><span class="glyph">●</span>In an initial trial conducted by the Veteran's Administration, 121 patients with stage I bladder cancer were randomly assigned to oral <a class="drug drug_general" data-topicid="9839" href="/d/drug information/9839.html" rel="external">pyridoxine</a>, placebo, or intravesical <a class="drug drug_general" data-topicid="9992" href="/d/drug information/9992.html" rel="external">thiotepa</a> [<a href="#rid29">29</a>]. The percentage of patients with a recurrence was not significantly different among the three arms, although pyridoxine was better than placebo if recurrences during the first 10 months were excluded from the analysis, suggesting that pyridoxine may be useful for the prevention of new tumor formation rather than the treatment of existing tumors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Based on these results, the European Organisation for Research and Treatment of Cancer (EORTC) organized a larger trial in which 291 men with previously resected non-muscle invasive bladder cancer were randomly assigned to <a class="drug drug_general" data-topicid="9839" href="/d/drug information/9839.html" rel="external">pyridoxine</a> or placebo [<a href="#rid30">30</a>]. The use of pyridoxine had no significant effect on the time to first recurrence or the overall recurrence rate, even after adjusting for urinary levels of tryptophan metabolites.</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Ascorbic acid</span><span class="headingEndMark"> — </span>Ascorbic acid (<a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a>) is a reducing agent that acts as a free radical scavenger; in particular, vitamin C decreases the formation of N-nitroso chemicals that are associated with bladder cancer carcinogenesis. Despite this, high levels of sodium ascorbate were associated with an increased incidence of bladder cancer in rats [<a href="#rid31">31</a>]. Whether these findings are relevant to humans is unclear.</p><p>The epidemiologic data are conflicting [<a href="#rid32">32-35</a>], and no randomized prospective trials exist to evaluate the role of <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> as a chemopreventative agent.</p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort of 11,580 cancer-free older adult subjects followed over an eight-year period, the use of <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> supplements was associated with a decreased incidence of bladder cancer [<a href="#rid32">32</a>]. Two case-control series also suggested that vitamin C might offer some protection against bladder cancer [<a href="#rid33">33,34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, the prospective Cancer Prevention Study II (CPS II) failed to identify any benefit from the use of <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> in a cohort of over 990,000 subjects followed for up to 16 years [<a href="#rid35">35</a>]. The use of vitamin C supplements ≥15 times per month was not associated with a decrease in bladder cancer mortality. Similarly, a dietary analysis of patients enrolled in the ATBC Study failed to identify any protective effect associated with increased levels of vitamin C intake [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Alpha-tocopherol</span><span class="headingEndMark"> — </span>Alpha-tocopherol (<a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>) is an antioxidant and inhibits carcinogenic N-nitroso formation in vitro. These observations provide a rationale for the use of alpha-tocopherol in preventing urothelial transformation.</p><p>Epidemiologic data suggest that diets high in alpha-tocopherol are associated with a lower risk of bladder cancer [<a href="#rid35">35,37,38</a>]. In the largest epidemiologic study, over 990,000 United States adults were evaluated as part of the CPS II cohort [<a href="#rid35">35</a>]. The major finding was that regular <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> supplementation for more than 10 years was associated with a reduced risk of bladder cancer mortality. This finding was more pronounced in ex-smokers and current smokers than in nonsmokers, suggesting some protection from carcinogens associated with smoking. Use for shorter periods of time was not associated with a reduction in disease-specific mortality.</p><p>However, no benefits have been observed in prospective clinical trials [<a href="#rid22">22,39</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In the ATBC Study, over 29,000 male smokers were randomly assigned to alpha-tocopherol, <a class="drug drug_general" data-topicid="9127" href="/d/drug information/9127.html" rel="external">beta-carotene</a>, both, or placebo [<a href="#rid21">21,22</a>]. There were no statistically significant differences in the incidence of bladder cancer between the groups. However, the dose of alpha-tocopherol used in this trial was lower than that of typical daily supplements (50 versus 200 to 1000 international units).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a secondary analysis of the <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">Selenium</a> and <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> Cancer Prevention Trial (SELECT), higher doses (400 international units) of vitamin E, either alone or in combination with selenium, failed to demonstrate a protective effect against bladder cancer in 34,887 men [<a href="#rid39">39</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Multivitamins</span><span class="headingEndMark"> — </span>The theoretical benefits of vitamin supplementation for cancer prevention led to the idea that a combination of vitamins might prove more powerful than any single nutrient. However, the results of various studies have not been consistent.</p><p class="bulletIndent1"><span class="glyph">●</span>A role in primary prevention was suggested by a case-control study that included 262 patients and 405 controls, which reported that the daily use of multivitamin supplements for more than 10 years was associated with a decrease in the risk of bladder cancer (odds ratio [OR] 0.39, 95% CI 0.24-0.63) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The potential for multivitamins in secondary chemoprevention was suggested by a prospective trial in which 65 patients treated for non-invasive bladder cancer were given <a class="drug drug_general" data-topicid="102734" href="/d/drug information/102734.html" rel="external">intravesical Bacillus Calmette-Guerin</a> (BCG) [<a href="#rid40">40</a>]. Patients were randomly assigned to a recommended daily allowance multivitamin or to a megadose vitamin (ie, augmented levels of vitamins A, B6, C, E, and zinc). Although there was no difference between the two regimens in the first year, patients receiving the megadose vitamin had a statistically significant lower rate of recurrence at five years (41 versus 91 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, in a larger multicenter prospective trial in BCG-naïve patients receiving <a class="drug drug_general" data-topicid="102734" href="/d/drug information/102734.html" rel="external">intravesical BCG</a> (with or without interferon treatment), compared with vitamins dosed at the recommended daily allowance, there was no benefit to the administration of megadose multivitamins [<a href="#rid41">41</a>].</p><p></p><p class="headingAnchor" id="H180971677"><span class="h2">Selenium</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">Selenium</a> is required for the activity of glutathione peroxidase, which converts lipid hydroperoxides into nontoxic alcohols and hydrogen peroxide into water and oxygen. Glutathione peroxidase may also provide a direct protective effect against carcinogens in the bladder by neutralizing their oxidative potential.</p><p>Several large studies correlating the incidence of bladder cancer and serum <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a> levels (or toenail concentrations, a surrogate measure of selenium intake during the previous 12 months) have yielded conflicting results:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a> concentrations were associated with a decreased risk of bladder cancer in several studies [<a href="#rid42">42-44</a>], with the effect being more pronounced in those with invasive bladder cancer and in ex-smokers [<a href="#rid42">42</a>]. A Belgian case-control study of 178 cases and 362 controls examining serum selenium levels supported these findings [<a href="#rid43">43</a>]. Patients were divided into tertiles by selenium level, and the middle and highest groups demonstrated a significantly decreased incidence of bladder cancer compared with the lowest group. A Turkish case-control study of serum selenium levels showed that those with grade 2 to 3 bladder cancer had lower levels than those with grade 1 cancers or the normal controls [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, the Nurses' Health Study reported that women who developed bladder cancer actually had higher levels of toenail <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a> than the control population [<a href="#rid45">45</a>]. More importantly, a secondary analysis of the SELECT trial did not reveal a role for selenium, alone or in combination with <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>, for the primary chemoprevention of bladder cancer in men [<a href="#rid39">39</a>].</p><p></p><p>The potential role of <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a> for secondary chemoprevention was evaluated in the Selenium and Bladder Cancer Trial (SELEBLAT) [<a href="#rid46">46,47</a>]. In this trial, 292 patients who had undergone transurethral resection of a non-muscle invasive urothelial carcinoma were randomly assigned to selenium (200 mcg/day selenium yeast) or placebo. At a median follow-up of 18 months, there was no significant difference in the rate of recurrence (28 versus 32 percent, respectively, for selenium and placebo).</p><p class="headingAnchor" id="H14"><span class="h2">Difluoromethylornithine</span><span class="headingEndMark"> — </span>Polyamine synthesis is associated with the induction of urothelial cell cancer in experimental models [<a href="#rid48">48</a>]. Difluoromethylornithine (DFMO) irreversibly inhibits ornithine decarboxylase, an enzyme that is required for polyamine synthesis [<a href="#rid49">49</a>].</p><p>DFMO was evaluated as a secondary chemopreventive agent in a randomized trial in which 454 patients with newly diagnosed or recurrent, Ta or T1, grade 1 to 2 bladder cancer were randomly assigned to treatment with DFMO or placebo for one year following resection of their bladder cancer [<a href="#rid49">49</a>]. At a median follow-up of 42 months, DFMO did not decrease the incidence of tumor recurrence (46 versus 43 percent with placebo), nor were any benefits observed in terms of the number of patients with progression to carcinoma in situ or grade 3 disease.</p><p class="headingAnchor" id="H15"><span class="h2">Nonsteroidal antiinflammatory drugs</span><span class="headingEndMark"> — </span>Cyclooxygenases catalyze the synthesis of prostaglandins from arachidonic acid. The effects of prostaglandin synthesis may include increased angiogenesis, inhibition of apoptosis, and decreased immune surveillance, all of which may contribute to carcinogenesis. Although preclinical data suggest a possible benefit [<a href="#rid50">50,51</a>], no clinical trial to date has demonstrated a benefit for secondary chemoprevention.</p><p><a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">Celecoxib</a>, a selective cyclooxygenase 2 (COX-2) inhibitor, was evaluated as a secondary chemopreventive agent in a phase IIB clinical trial in which 146 patients with non-muscle invasive bladder cancer who achieved an initial complete response to induction BCG followed by three weeks of maintenance BCG were randomized to celecoxib 200 mg daily or placebo. In this setting, no benefit in time to recurrence or recurrence rate was demonstrated [<a href="#rid52">52</a>]. Although there was hope that the lower incidence of gastrointestinal side effects would indicate a superior therapeutic index in favor of using the selective COX-2 inhibitors, they have been associated with increased cardiovascular risk in some trials. Despite this, there was no increased risk demonstrated in this trial, and celecoxib remains available in some areas of the world.</p><p>This study was followed by a phase III clinical trial in London in which 475 patients with non-muscle invasive bladder cancer who achieved a complete response to resection and induction BCG were randomized to <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> at a higher dose (400 mg daily or 200 mg twice daily) or placebo. However, the results of this trial have not yet been released [<a href="#rid53">53</a>]. Overall, it seems unlikely that selective COX-2 inhibitors will find widespread use in cancer prevention for an otherwise healthy population. (See  <a class="medical medical_review" href="/d/html/2600.html" rel="external">"NSAIDs (including aspirin): Role in prevention of colorectal cancer"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Isoflavones</span><span class="headingEndMark"> — </span>Isoflavones are natural substances derived from soy protein that are excreted in the urine. A reduced risk of breast, colon, and prostate cancers has been observed in populations with higher levels of soy consumption [<a href="#rid54">54</a>]. In addition, animal experiments indicate that soy protein diets have a protective effect against bladder carcinogenesis, and cell cycle studies show that these agents can induce apoptosis in immortalized bladder cancer cells [<a href="#rid55">55</a>].</p><p>However, the limited available clinical evidence does not support a chemoprotective effect from soy protein or isoflavone supplementation on bladder cancer incidence in men. In an epidemiologic study from China involving 18,244 men, a higher risk of bladder cancer was reported in patients consuming more dietary soy daily compared with less frequent intake after adjustment for age, tobacco use, and education level [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Polyphenols</span><span class="headingEndMark"> — </span>Polyphenols are powerful antioxidant compounds that are found in green and black tea. (See  <a class="medical medical_review" href="/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm"</a>.)</p><p>Animal studies have shown that green tea leaves inhibit carcinogen-induced bladder tumor formation [<a href="#rid57">57</a>]; however, human epidemiologic studies remain conflicting on the benefit of tea extracts. A 2013 meta-analysis of 17 studies concluded that tea consumption had no impact on bladder cancer risk; however, when the green tea subgroup was analyzed, a protective effect against bladder cancer was observed [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H180971797"><span class="h2">Statins</span><span class="headingEndMark"> — </span>Cholesterol-lowering agents such as hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) have been shown to decrease the risk of various cancers. No epidemiologic or clinical studies exist to support their use for primary [<a href="#rid59">59-61</a>] or secondary [<a href="#rid62">62</a>] prevention of bladder cancer.</p><p class="headingAnchor" id="H2565975151"><span class="h2">Antiandrogens</span><span class="headingEndMark"> — </span>Bladder cancer is threefold more common in males, which cannot be explained entirely by differences in exposure to tobacco and other carcinogens between males and females. Data suggest that androgens may promote urothelial carcinogenesis. <a class="drug drug_general" data-topicid="86370" href="/d/drug information/86370.html" rel="external">Enzalutamide</a>, an inhibitor of the androgen axis, was under investigation for secondary chemoprevention in patients with non-muscle invasive bladder cancer; however, the trial was terminated due to poor accrual [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale</strong> – The etiologic risk factors for bladder cancer include smoking and various environmental and occupational carcinogens. These substances are concentrated in the urine, where the urothelial lining is exposed to their carcinogenic effects. (See <a class="local">'Rationale'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemopreventive agents</strong> – Many substances have been assessed for their ability to prevent de novo bladder cancer (primary chemoprevention) or recurrence after an earlier diagnosis (secondary chemoprevention). However, none of these should be used in either of these settings outside of a clinical trial. (See <a class="local">'Chemopreventive agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary prevention</strong> – Smoking cessation, increased fluid intake, weight loss, and a healthy diet that is low in fat and high in fruits and vegetables should be recommended to all patients for primary prevention of bladder cancer. (See  <a class="medical medical_review" href="/d/html/2957.html" rel="external">"Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder", section on 'Risk factors'</a>.)</p><p></p><p class="headingAnchor" id="H26421006"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges J Stephen Jones, MD, and Juan Jiménez, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Besaratinia A, Tommasi S. Genotoxicity of tobacco smoke-derived aromatic amines and bladder cancer: current state of knowledge and future research directions. FASEB J 2013; 27:2090.</a></li><li><a class="nounderline abstract_t">Skipper PL, Tannenbaum SR, Ross RK, Yu MC. Nonsmoking-related arylamine exposure and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12:503.</a></li><li><a class="nounderline abstract_t">Tao L, Day BW, Hu B, et al. Elevated 4-aminobiphenyl and 2,6-dimethylaniline hemoglobin adducts and increased risk of bladder cancer among lifelong nonsmokers--The Shanghai Bladder Cancer Study. Cancer Epidemiol Biomarkers Prev 2013; 22:937.</a></li><li><a class="nounderline abstract_t">Michaud DS, Spiegelman D, Clinton SK, et al. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst 1999; 91:605.</a></li><li><a class="nounderline abstract_t">Veeranki OL, Bhattacharya A, Tang L, et al. Cruciferous vegetables, isothiocyanates, and prevention of bladder cancer. Curr Pharmacol Rep 2015; 1:272.</a></li><li><a class="nounderline abstract_t">Leone A, Diorio G, Sexton W, et al. Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach. Oncotarget 2017; 8:35412.</a></li><li><a class="nounderline abstract_t">Abbaoui B, Lucas CR, Riedl KM, et al. Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention. Mol Nutr Food Res 2018; 62:e1800079.</a></li><li><a class="nounderline abstract_t">Zhou J, Smith S, Giovannucci E, Michaud DS. Reexamination of total fluid intake and bladder cancer in the Health Professionals Follow-up Study Cohort. Am J Epidemiol 2012; 175:696.</a></li><li><a class="nounderline abstract_t">Steinmaus CM, Nuñez S, Smith AH. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 2000; 151:693.</a></li><li><a class="nounderline abstract_t">Koebnick C, Michaud D, Moore SC, et al. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2008; 17:1214.</a></li><li><a class="nounderline abstract_t">Yuan JM, Chan KK, Coetzee GA, et al. Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Carcinogenesis 2008; 29:1386.</a></li><li><a class="nounderline abstract_t">Clapp RW, Jacobs MM, Loechler EL. Environmental and occupational causes of cancer: new evidence 2005-2007. Rev Environ Health 2008; 23:1.</a></li><li><a class="nounderline abstract_t">Vickers AJ, Bennette C, Kibel AS, et al. Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Cancer 2013; 119:143.</a></li><li><a class="nounderline abstract_t">Mir MC, Stephenson AJ, Grubb RL 3rd, et al. Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. Cancer Epidemiol Biomarkers Prev 2013; 22:2241.</a></li><li><a class="nounderline abstract_t">Khajeh NR, Khoyilar C, Wu Y, et al. Bladder Cancer Chemopreventive Agents: Current Knowledge and Concepts. Mini Rev Med Chem 2018; 18:1143.</a></li><li><a class="nounderline abstract_t">Lotan R, Clifford JL. Nuclear receptors for retinoids: mediators of retinoid effects on normal and malignant cells. Biomed Pharmacother 1991; 45:145.</a></li><li><a class="nounderline abstract_t">Cohen SM, Wittenberg JF, Bryan GT. Effect of avitaminosis A and hypervitaminosis A on urinary bladder carcinogenicity of N-(4-(5-Nitro-2-furyl)-2-thiazolyl)formamide. Cancer Res 1976; 36:2334.</a></li><li><a class="nounderline abstract_t">Sporn MB, Squire RA, Brown CC, et al. 13-cis-retinoic acid: inhibition of bladder carcinogenesis in the rat. Science 1977; 195:487.</a></li><li><a class="nounderline abstract_t">Becci PJ, Thompson HJ, Grubbs CJ, et al. Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Res 1978; 38:4463.</a></li><li><a class="nounderline abstract_t">Mathews-Roth MM, Lausen N, Drouin G, et al. Effects of carotenoid administration on bladder cancer prevention. Oncology 1991; 48:177.</a></li><li><a class="nounderline abstract_t">Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029.</a></li><li><a class="nounderline abstract_t">Virtamo J, Edwards BK, Virtanen M, et al. Effects of supplemental alpha-tocopherol and beta-carotene on urinary tract cancer: incidence and mortality in a controlled trial (Finland). Cancer Causes Control 2000; 11:933.</a></li><li><a class="nounderline abstract_t">Alfthan O, Tarkkanen J, Gröhn P, et al. Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial. Eur Urol 1983; 9:6.</a></li><li><a class="nounderline abstract_t">Studer UE, Jenzer S, Biedermann C, et al. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 1995; 28:284.</a></li><li><a class="nounderline abstract_t">Sabichi AL, Lerner SP, Atkinson EN, et al. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res 2008; 14:224.</a></li><li><a class="nounderline abstract_t">Decensi A, Torrisi R, Bruno S, et al. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol Biomarkers Prev 2000; 9:1071.</a></li><li><a class="nounderline abstract_t">Tratnjek L, Jeruc J, Romih R, Zupančič D. Vitamin A and Retinoids in Bladder Cancer Chemoprevention and Treatment: A Narrative Review of Current Evidence, Challenges and Future Prospects. Int J Mol Sci 2021; 22.</a></li><li><a class="nounderline abstract_t">Yoshida O, Brown RR, Bryan GT. Relationship between tryptophan metabolism and heterotopic recurrences of human urinary bladder tumors. Cancer 1970; 25:773.</a></li><li><a class="nounderline abstract_t">Byar D, Blackard C. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 1977; 10:556.</a></li><li><a class="nounderline abstract_t">Newling DW, Robinson MR, Smith PH, et al. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1995; 27:110.</a></li><li><a class="nounderline abstract_t">Fukushima S, Imaida K, Sakata T, et al. Promoting effects of sodium L-ascorbate on two-stage urinary bladder carcinogenesis in rats. Cancer Res 1983; 43:4454.</a></li><li><a class="nounderline abstract_t">Shibata A, Paganini-Hill A, Ross RK, Henderson BE. Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study. Br J Cancer 1992; 66:673.</a></li><li><a class="nounderline abstract_t">Nomura AM, Kolonel LN, Hankin JH, Yoshizawa CN. Dietary factors in cancer of the lower urinary tract. Int J Cancer 1991; 48:199.</a></li><li><a class="nounderline abstract_t">Bruemmer B, White E, Vaughan TL, Cheney CL. Nutrient intake in relation to bladder cancer among middle-aged men and women. Am J Epidemiol 1996; 144:485.</a></li><li><a class="nounderline abstract_t">Jacobs EJ, Henion AK, Briggs PJ, et al. Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 2002; 156:1002.</a></li><li><a class="nounderline abstract_t">Michaud DS, Pietinen P, Taylor PR, et al. Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study. Br J Cancer 2002; 87:960.</a></li><li><a class="nounderline abstract_t">Liang D, Lin J, Grossman HB, et al. Plasma vitamins E and A and risk of bladder cancer: a case-control analysis. Cancer Causes Control 2008; 19:981.</a></li><li><a class="nounderline abstract_t">Michaud DS, Spiegelman D, Clinton SK, et al. Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am J Epidemiol 2000; 152:1145.</a></li><li><a class="nounderline abstract_t">Lotan Y, Goodman PJ, Youssef RF, et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. J Urol 2012; 187:2005.</a></li><li><a class="nounderline abstract_t">Lamm DL, Riggs DR, Shriver JS, et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994; 151:21.</a></li><li><a class="nounderline abstract_t">Nepple KG, Lightfoot AJ, Rosevear HM, et al. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 2010; 184:1915.</a></li><li><a class="nounderline abstract_t">Zeegers MP, Goldbohm RA, Bode P, van den Brandt PA. Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 2002; 11:1292.</a></li><li><a class="nounderline abstract_t">Kellen E, Zeegers M, Buntinx F. Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. Int J Urol 2006; 13:1180.</a></li><li><a class="nounderline abstract_t">Yalçin O, Karataş F, Erulaş FA, Ozdemir E. The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. BJU Int 2004; 93:863.</a></li><li><a class="nounderline abstract_t">Garland M, Morris JS, Stampfer MJ, et al. Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 1995; 87:497.</a></li><li><a class="nounderline abstract_t">Goossens ME, Buntinx F, Joniau S, et al. Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. BMC Urol 2012; 12:8.</a></li><li><a class="nounderline abstract_t">Goossens ME, Zeegers MP, van Poppel H, et al. Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial. Eur J Cancer 2016; 69:9.</a></li><li><a class="nounderline abstract_t">Messing EM, Hanson P, Reznikoff CA. Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion. Cancer Res 1988; 48:357.</a></li><li><a class="nounderline abstract_t">Messing E, Kim KM, Sharkey F, et al. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006; 176:500.</a></li><li><a class="nounderline abstract_t">Dovedi SJ, Kirby JA, Davies BR, et al. Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Eur Urol 2008; 54:621.</a></li><li><a class="nounderline abstract_t">Madka V, Asch AS, Rao CV. Targeting inflammation for bladder cancer chemoprevention. Curr Pharmacol Rep 2017.</a></li><li><a class="nounderline abstract_t">Sabichi AL, Lee JJ, Grossman HB, et al. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) 2011; 4:1580.</a></li><li><a class="nounderline abstract_t">Kelly JD, Hall E. Boxing bladder cancer with COX-2-specific inhibition. Cancer Prev Res (Phila) 2011; 4:1534.</a></li><li><a class="nounderline abstract_t">Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991; 83:541.</a></li><li><a class="nounderline abstract_t">Theodorescu D, Laderoute KR, Calaoagan JM, Guilding KM. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. Int J Cancer 1998; 78:775.</a></li><li><a class="nounderline abstract_t">Sun CL, Yuan JM, Wang XL, et al. Dietary soy and increased risk of bladder cancer: a prospective cohort study of men in Shanghai, China. Int J Cancer 2004; 112:319.</a></li><li><a class="nounderline abstract_t">Sato D, Matsushima M. Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves. Int J Urol 2003; 10:160.</a></li><li><a class="nounderline abstract_t">Wang X, Lin YW, Wang S, et al. A meta-analysis of tea consumption and the risk of bladder cancer. Urol Int 2013; 90:10.</a></li><li><a class="nounderline abstract_t">Zhang XL, Geng J, Zhang XP, et al. Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control 2013; 24:769.</a></li><li><a class="nounderline abstract_t">Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 2011; 71:1763.</a></li><li><a class="nounderline abstract_t">Chen J, Zhang B, Chen D, Zhuang W. The association of statin use with risk of kidney, bladder and prostate cancer: A systematic review and meta-analysis of cohort studies. Int J Clin Exp Med 2018; 11:8873.</a></li><li><a class="nounderline abstract_t">Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU Int 2013; 112:E4.</a></li><li class="breakAll">Enzalutamide for Bladder Cancer Chemoprevention. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02605863 (Accessed on October 07, 2021).</li></ol></div><div id="topicVersionRevision">Topic 2971 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23449930" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Genotoxicity of tobacco smoke-derived aromatic amines and bladder cancer: current state of knowledge and future research directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814994" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nonsmoking-related arylamine exposure and bladder cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23539508" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Elevated 4-aminobiphenyl and 2,6-dimethylaniline hemoglobin adducts and increased risk of bladder cancer among lifelong nonsmokers--The Shanghai Bladder Cancer Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10203279" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26273545" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cruciferous vegetables, isothiocyanates, and prevention of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28423681" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30079608" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22355034" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reexamination of total fluid intake and bladder cancer in the Health Professionals Follow-up Study Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10752797" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diet and bladder cancer: a meta-analysis of six dietary variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18483344" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Body mass index, physical activity, and bladder cancer in a large prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18544563" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18557596" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Environmental and occupational causes of cancer: new evidence 2005-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22736219" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24089460" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26975668" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bladder Cancer Chemopreventive Agents: Current Knowledge and Concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1657236" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Nuclear receptors for retinoids: mediators of retinoid effects on normal and malignant cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1277139" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of avitaminosis A and hypervitaminosis A on urinary bladder carcinogenicity of N-(4-(5-Nitro-2-furyl)-2-thiazolyl)formamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/835006" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : 13-cis-retinoic acid: inhibition of bladder carcinogenesis in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/719631" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1902559" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of carotenoid administration on bladder cancer prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8127329" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11142528" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effects of supplemental alpha-tocopherol and beta-carotene on urinary tract cancer: incidence and mortality in a controlled trial (Finland).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6337054" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8575494" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18172274" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11045790" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33805295" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Vitamin A and Retinoids in Bladder Cancer Chemoprevention and Treatment: A Narrative Review of Current Evidence, Challenges and Future Prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5443101" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Relationship between tryptophan metabolism and heterotopic recurrences of human urinary bladder tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/414402" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7744151" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6871876" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Promoting effects of sodium L-ascorbate on two-stage urinary bladder carcinogenesis in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1419605" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intake of vegetables, fruits, beta-carotene, vitamin C and vitamin supplements and cancer incidence among the elderly: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2019466" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Dietary factors in cancer of the lower urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8781464" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nutrient intake in relation to bladder cancer among middle-aged men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12446256" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12434284" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18478342" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Plasma vitamins E and A and risk of bladder cancer: a case-control analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11130620" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22498220" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8254816" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Megadose vitamins in bladder cancer: a double-blind clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846688" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bacillus Calmette-Guérin with or without interferonα-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12433705" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prediagnostic toenail selenium and risk of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16984549" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15050006" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7707436" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prospective study of toenail selenium levels and cancer among women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22436453" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27814472" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3275496" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16813878" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18222600" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Targeting inflammation for bladder cancer chemoprevention</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21881030" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21896649" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Boxing bladder cancer with COX-2-specific inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1672382" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The role of soy products in reducing risk of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9833772" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15352046" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dietary soy and increased risk of bladder cancer: a prospective cohort study of men in Shanghai, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622713" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23052791" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A meta-analysis of tea consumption and the risk of bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23361339" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Statin use and risk of bladder cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343395" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The association of statin use with risk of kidney, bladder and prostate cancer: A systematic review and meta-analysis of cohort studies</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23795797" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of statin use on outcomes of non-muscle-invasive bladder cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
